Clinical trials: Non-hodgkin Lymphoma,B Cell
B-Cell Non-Hodgkin Lymphoma
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory…
- Trial name
- NCT07658352
- Testing
- HP-002
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shanghai Helioson Pharmaceutical Co., Ltd.
B Cell Lymphoma
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients.
- Trial name
- NCT03258047
- Testing
- CAR-T
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC combining with auto-HSCT to treat aggressive lymphoma Subjects
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma, Double-hit Lymphoma
- Trial name
- NCT03629873
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
B Cell Lymphoma, Follicular Lymphoma
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops.
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Neoplasm
- Trial name
- NCT00001572
- Testing
- Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients with first relapsed/refractory mantle cell lymphoma…
- Trial name
- R2-B (NCT01737177)
- Testing
- Bendamustine, Lenalidomide, Rituximab
- Where
- 43 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
B-cell Acute Lymphoblastic Leukemia
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue.
- Trial name
- NCT05470777
- Testing
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Soochow University
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in…
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00004241
- Testing
- tanespimycin, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01116154
- Testing
- lenalidomide, vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Chronic, Myeloid Leukemia
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase…
- Conditions
- Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT04260022
- Testing
- Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab
- Where
- 9 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- Ascentage Pharma Group Inc.
Lymphoma
Bone Marrow Transplantation in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for…
- Trial name
- NCT00002829
- Testing
- Recombinant Interferon Alfa, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
Experimental Bone Marrow Transplant Protocol
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00061581
- Testing
- Isolex 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
This phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating patients with relapsed or refractory low-grade B-cell…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02049541
- Testing
- PI3K inhibitor BKM120, rituximab, Pharmacodynamics
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Kami Maddocks, MD
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Lymphoma, Burkitt Lymphoma
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone…
- Trial name
- LONCA (NCT05270057)
- Testing
- Etoposide, Doxorubicin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Medical College of Wisconsin
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety…
- Conditions
- Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood
- Trial name
- NCT04204161
- Testing
- CAR-T19/CAR-T22
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
- Trial name
- NCT05131022
- Testing
- NX-5948
- Where
- 62 sites in United States, France and 6 more
- Volunteers
- 572 people
- Sponsor
- Nurix Therapeutics, Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs…
- Trial name
- NCT05366257
- Testing
- CAR-T, Allo-HSCT cohort
- Where
- United States
- Volunteers
- 160,602 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.